




Atara Biotherapeutics
Investor Relations Department
701 Gateway Blvd, Suite 200
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ATRA

Last Trade:	15.05
Trade Time:	12:42 PM ET Jul 28, 2017
Change:	-0.15  (-0.987%)
Day Range	14.65 - 15.25
52-Week Range	11.80 - 25.73
Volume	100,537


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company's stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

May 24, 2017

[Atara Biotherapeutics to Present at Three Upcoming Investor Conferences](#)

May 10, 2017

[Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

May 10, 2017

[Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team](#)

May 4, 2017

[Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights](#)

Upcoming Events [\[View all \]](#)

Aug 9, 2017

[Canaccord Genuity Growth Conference](#)

Sep 6, 2017

[CAR-TCR Summit 2017](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)